


M13 Reverse priming site Mlu I
 201 CACA CAGGAA ACAGCTATGA CATGATTAC GCCAAGCTAT TTAGGTGACG CGTTAGAATA
 GTGT GTCCCTT TGTCGATACT GTACTAATG CGGTTTCGATA AATCCACTGC GCAATCTTAT
 Nsi I Hind III Kpn I *Ecl36* II Sac I BamH I Spe I
 261 CTCAAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT
 GAGTTCGATA CGTAGTTCGA ACCATGGCTC GAGCCTAGGT GATCATTGCC GGCGGTCACA
EcoR I *EcoR* I Pst I *EcoR* V
 321 GCTGGAATTC GCC CTT **XL PCR Product** AAG GGC GAATTCT GCAGATA
 CGACCTTAAG CGG GAA TTC CCG CTTAAGA CGTCTAT
 Not I Xho I Nsi I Xba I Dra II Apa I T7 promoter/priming site
 357 TCCATCACAC TGGCGGCCCG TCGAGCATGC ATCTAGAGGG CCCAATTCGC CCTATAGTGA
 AGGTAGTGTG ACCGCCGCG AGCTCGTACG TAGATCTCC GGGTTAAGCG GGATATCACT
 M13 Forward (-20) priming site
 417 GTCGTATTAC AATTC ACTGG CCGTCGTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT 470
 CAGCATAA TG TTAAGT GACC GGCAGCAAAA TG TTGCAGCA CTGACCCTTT TGGGACCGCA



**Comments for pCR[®]-XL-TOPO[®]
3519 nucleotides**

Lac promoter/operator region: bases 95-216
 M13 Reverse priming site: bases 205-221
 Lac Za ORF: bases 217-576
 Multiple Cloning Site: bases 248-399
 TOPO[®] Cloning site: bases 336-337
 T7 promoter priming site: bases 406-425
 M13 Forward (-20) priming site: bases 433-448
 Fusion joint: bases 577-585
ccaB lethal gene ORF: bases 586-888
 Kanamycin resistance ORF: bases 1237-2031
 Zeocin resistance ORF: bases 2238-2612
 pUC origin: bases 2680-3393